HRTX Q4 2024 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$162M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$41M+19.1% YoY

Gross Profit

$31M74.9% margin

Operating Income

$4M10.2% margin

Net Income

$4M9.0% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

+24.3%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$233M

Total Liabilities

$267M

Stockholders' Equity

-$34M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$34M	+19.1%
Gross Profit	$31M	$24M	+25.5%
Operating Income	$4M	-$10M	+140.8%
Net Income	$4M	-$11M	+134.2%

Revenue Segments

C I N V A N T I

$52M70%

Z Y N R E L E F

$14M19%

S U S T O L

$8M11%